Brian Lian - 20 Sep 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
President & CEO, Director
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
20 Sep 2024
Net transactions value
-$14,017,723
Form type
4
Filing time
20 Sep 2024, 21:20:57 UTC
Previous filing
22 Aug 2024
Next filing
06 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $1,290,830 +166,130 +7.1% $7.77 2,521,057 20 Sep 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale $6,765,109 -96,056 -3.8% $70.43 2,425,001 20 Sep 2024 Direct F1, F2
transaction VKTX Common Stock, par value $0.00001 per share Sale $8,529,047 -119,874 -4.9% $71.15 2,305,127 20 Sep 2024 Direct F1, F3
transaction VKTX Common Stock, par value $0.00001 per share Sale $14,397 -200 -0.01% $71.98 2,304,927 20 Sep 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -166,130 -72% $0.000000 65,000 20 Sep 2024 Common Stock 166,130 $7.77 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.90 to $70.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.90 to $71.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.97 to $72.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 25% of the shares subject to the option vested on each anniversary of the grant date.